Splenic vein thrombosis medical therapy: Difference between revisions
Jump to navigation
Jump to search
Sunny Kumar (talk | contribs) |
Sunny Kumar (talk | contribs) |
||
| Line 17: | Line 17: | ||
*'''2.1 Chronic splenic vein thrombosis''' | *'''2.1 Chronic splenic vein thrombosis''' | ||
**2.1.1 Chronic splenic vein thrombosis with [[hypercoagulable state]] or previous history of [[vascular disease]] | ***2.1.1 Chronic splenic vein thrombosis with [[hypercoagulable state]] or previous history of [[vascular disease]] | ||
**2.1.1.1 Long term [[anticoagulation]] | ****2.1.1.1 Long term [[anticoagulation]] | ||
**Preferred regimen: [[Warfarin]] 2-5 mg PO q24h | *****Preferred regimen: [[Warfarin]] 2-5 mg PO q24h | ||
**2.1.1.2 [[Gastric varices #Treatment|Treatment ofGastric varices]] | ****2.1.1.2 [[Gastric varices #Treatment|Treatment ofGastric varices]] | ||
**2.1.2. Chronic splenic vein thrombosis without [[hypercoagulable state]] or previous history of [[vascular disease]] | ***2.1.2. Chronic splenic vein thrombosis without [[hypercoagulable state]] or previous history of [[vascular disease]] | ||
**'''NOTE:''' Chronic anticoagulation is generally not recommended | **'''NOTE:''' Chronic anticoagulation is generally not recommended | ||
**2.1.2.1 [[Gastric varices #Treatment|Treatment of gastric varices]] | ***2.1.2.1 [[Gastric varices #Treatment|Treatment of gastric varices]] | ||
*'''2.2 Acute splenic vein thrombosis''' | **'''2.2 Acute splenic vein thrombosis''' | ||
**2.1 [[Anticoagulant therapy]] | ***2.1 [[Anticoagulant therapy]] | ||
***2.1.1 Acute splenic vein thrombosis with [[hypercoagulable state]] | ****2.1.1 Acute splenic vein thrombosis with [[hypercoagulable state]] | ||
***Preferred regimen: [[Warfarin]] 2-5 mg PO q24h for long term | *****Preferred regimen: [[Warfarin]] 2-5 mg PO q24h for long term | ||
***2.2.2 Acute splenic vein thrombosis without [[hypercoagulable state]] | ****2.2.2 Acute splenic vein thrombosis without [[hypercoagulable state]] | ||
***Preferred regimen: [[Warfarin]] 2-5 mg PO q24h for 3-6 months | *****Preferred regimen: [[Warfarin]] 2-5 mg PO q24h for 3-6 months | ||
**2.2 [[Thrombolytic therapy]] | ***2.2 [[Thrombolytic therapy]] | ||
*** Preferred regimen: [[recombinant tissue plasminogen activator|Recombinant tissue plasminogen activator (RTPA)]]<ref name="pmid14681650">{{cite journal |vauthors=Henao EA, Bohannon WT, Silva MB |title=Treatment of portal venous thrombosis with selective superior mesenteric artery infusion of recombinant tissue plasminogen activator |journal=J. Vasc. Surg. |volume=38 |issue=6 |pages=1411–5 |year=2003 |pmid=14681650 |doi=10.1016/S0741 |url=}}</ref> | ***:* Preferred regimen: [[recombinant tissue plasminogen activator|Recombinant tissue plasminogen activator (RTPA)]]<ref name="pmid14681650">{{cite journal |vauthors=Henao EA, Bohannon WT, Silva MB |title=Treatment of portal venous thrombosis with selective superior mesenteric artery infusion of recombinant tissue plasminogen activator |journal=J. Vasc. Surg. |volume=38 |issue=6 |pages=1411–5 |year=2003 |pmid=14681650 |doi=10.1016/S0741 |url=}}</ref> | ||
***Alternate regimen(1): [[Urokinase]]<ref name="pmid11851847">{{cite journal |vauthors=Tateishi A, Mitsui H, Oki T, Morishita J, Maekawa H, Yahagi N, Maruyama T, Ichinose M, Ohnishi S, Shiratori Y, Minami M, Koutetsu S, Hori N, Watanabe T, Nagawa H, Omata M |title=Extensive mesenteric vein and portal vein thrombosis successfully treated by thrombolysis and anticoagulation |journal=J. Gastroenterol. Hepatol. |volume=16 |issue=12 |pages=1429–33 |year=2001 |pmid=11851847 |doi= |url=}}</ref> | ***:*Alternate regimen(1): [[Urokinase]]<ref name="pmid11851847">{{cite journal |vauthors=Tateishi A, Mitsui H, Oki T, Morishita J, Maekawa H, Yahagi N, Maruyama T, Ichinose M, Ohnishi S, Shiratori Y, Minami M, Koutetsu S, Hori N, Watanabe T, Nagawa H, Omata M |title=Extensive mesenteric vein and portal vein thrombosis successfully treated by thrombolysis and anticoagulation |journal=J. Gastroenterol. Hepatol. |volume=16 |issue=12 |pages=1429–33 |year=2001 |pmid=11851847 |doi= |url=}}</ref> | ||
***Alternate regimen(2): [[Streptokinase]]<ref name="pmid11851847">{{cite journal |vauthors=Tateishi A, Mitsui H, Oki T, Morishita J, Maekawa H, Yahagi N, Maruyama T, Ichinose M, Ohnishi S, Shiratori Y, Minami M, Koutetsu S, Hori N, Watanabe T, Nagawa H, Omata M |title=Extensive mesenteric vein and portal vein thrombosis successfully treated by thrombolysis and anticoagulation |journal=J. Gastroenterol. Hepatol. |volume=16 |issue=12 |pages=1429–33 |year=2001 |pmid=11851847 |doi= |url=}}</ref> The mainstay of [[therapy]] in [[splenic vein thrombosis]] with [[gastric varices]] is [[sclerotherapy]] and gastric banding | ***:*Alternate regimen(2): [[Streptokinase]]<ref name="pmid11851847">{{cite journal |vauthors=Tateishi A, Mitsui H, Oki T, Morishita J, Maekawa H, Yahagi N, Maruyama T, Ichinose M, Ohnishi S, Shiratori Y, Minami M, Koutetsu S, Hori N, Watanabe T, Nagawa H, Omata M |title=Extensive mesenteric vein and portal vein thrombosis successfully treated by thrombolysis and anticoagulation |journal=J. Gastroenterol. Hepatol. |volume=16 |issue=12 |pages=1429–33 |year=2001 |pmid=11851847 |doi= |url=}}</ref> | ||
*The mainstay of [[therapy]] in [[splenic vein thrombosis]] with [[gastric varices]] is [[sclerotherapy]] and gastric banding | |||
==References== | ==References== | ||
{{reflist|2}} | {{reflist|2}} | ||
Revision as of 00:07, 6 February 2018
|
Splenic vein thrombosis Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Splenic vein thrombosis medical therapy On the Web |
|
American Roentgen Ray Society Images of Splenic vein thrombosis medical therapy |
|
Risk calculators and risk factors for Splenic vein thrombosis medical therapy |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] ; Associate Editor(s)-in-Chief: Vindhya BellamKonda, M.B.B.S [2]
Overview
Medical therapy for splenic vein thrombosis include anti coagulation to maintain INR between 2 to 3. The goal of anticoagulation is to prevent extension of the clot and to allow for recanalization so that intestinal infarction and portal hypertension do not develop. The mainstay of therapy in splenic vein thrombosis with gastric varices is sclerotherapy and gastric banding
Medical therapy
Medical therapy for splenic vein thrombosis include anti coagulation to maintain INR between 2 to 3. The goal of anticoagulation is to prevent extension of the clot and to allow for recanalization so that intestinal infarction and portal hypertension do not develop. The mainstay of therapy in splenic vein thrombosis with gastric varices is sclerotherapy and gastric banding.[1][2][3][4][5]
- Correction of the causal factors
- Prevention of thrombosis extension
- Achievement of splenic vein patency
- Management of complications related to pancreatitis
- NOTE (1):Initiate anticoagulation with heparin for 3-4 weeks then start oral vitamin K antagonist(e.g. warfarin) to maintain INR between 2 to 3
- Improves re canalization rates
- Decrease development of gastric varices and complications associated with varices
- 2.1 Chronic splenic vein thrombosis
- 2.1.1 Chronic splenic vein thrombosis with hypercoagulable state or previous history of vascular disease
- 2.1.1.1 Long term anticoagulation
- Preferred regimen: Warfarin 2-5 mg PO q24h
- 2.1.1.2 Treatment ofGastric varices
- 2.1.1.1 Long term anticoagulation
- 2.1.2. Chronic splenic vein thrombosis without hypercoagulable state or previous history of vascular disease
- 2.1.1 Chronic splenic vein thrombosis with hypercoagulable state or previous history of vascular disease
- NOTE: Chronic anticoagulation is generally not recommended
- 2.1.2.1 Treatment of gastric varices
- 2.2 Acute splenic vein thrombosis
- 2.1 Anticoagulant therapy
- 2.1.1 Acute splenic vein thrombosis with hypercoagulable state
- Preferred regimen: Warfarin 2-5 mg PO q24h for long term
- 2.2.2 Acute splenic vein thrombosis without hypercoagulable state
- Preferred regimen: Warfarin 2-5 mg PO q24h for 3-6 months
- 2.1.1 Acute splenic vein thrombosis with hypercoagulable state
- 2.2 Thrombolytic therapy
- Preferred regimen: Recombinant tissue plasminogen activator (RTPA)[6]
- Alternate regimen(1): Urokinase[7]
- Alternate regimen(2): Streptokinase[7]
- 2.1 Anticoagulant therapy
- NOTE: Chronic anticoagulation is generally not recommended
- The mainstay of therapy in splenic vein thrombosis with gastric varices is sclerotherapy and gastric banding
References
- ↑ Bouvier A, Gout M, Audia S, Chalumeau C, Rat P, Deballon O (2017). "[Routine screening of splenic or portal vein thrombosis after splenectomy]". Rev Med Interne (in French). 38 (1): 3–7. doi:10.1016/j.revmed.2016.08.003. PMID 27639911.
- ↑ Valla D (2015). "Splanchnic Vein Thrombosis". Semin Thromb Hemost. 41 (5): 494–502. doi:10.1055/s-0035-1550439. PMID 26080307.
- ↑ Gouin B, Robert-Ebadi H, Casini A, Beauverd Y, Fontana P, Righini M; et al. (2017). "[Splanchnic vein thrombosis]". Rev Med Suisse. 13 (586): 2138–2143. PMID 29211374.
- ↑ Riva N, Ageno W (2017). "Approach to thrombosis at unusual sites: Splanchnic and cerebral vein thrombosis". Vasc Med. 22 (6): 529–540. doi:10.1177/1358863X17734057. PMID 29202678.
- ↑ Riva N, Donadini MP, Dentali F, Squizzato A, Ageno W (2012). "Clinical approach to splanchnic vein thrombosis: risk factors and treatment". Thromb Res. 130 Suppl 1: S1–3. doi:10.1016/j.thromres.2012.08.259. PMID 23026649.
- ↑ Henao EA, Bohannon WT, Silva MB (2003). "Treatment of portal venous thrombosis with selective superior mesenteric artery infusion of recombinant tissue plasminogen activator". J. Vasc. Surg. 38 (6): 1411–5. doi:10.1016/S0741. PMID 14681650.
- ↑ 7.0 7.1 Tateishi A, Mitsui H, Oki T, Morishita J, Maekawa H, Yahagi N, Maruyama T, Ichinose M, Ohnishi S, Shiratori Y, Minami M, Koutetsu S, Hori N, Watanabe T, Nagawa H, Omata M (2001). "Extensive mesenteric vein and portal vein thrombosis successfully treated by thrombolysis and anticoagulation". J. Gastroenterol. Hepatol. 16 (12): 1429–33. PMID 11851847.